Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ³ 18 years~* Low or intermediate-1 risk MDS according to IPSS, and FAB classification of RA, RARS, or RAEB with blasts £ 10%~* Predictive variables of good response (serum erythropoietin levels \< 500 IU/l and transfusion requirements \< 2 packed RBC/month over the preceding 2 months)~* Anaemia (Hb £ 10 g/dL), confirmed in the 14 days before day 1 of the study~* Life expectancy of at least 6 months~* ECOG Performance status score of 0, 1, or 2~* Subject must sign and date the Informed Consent (approved by a Clinical Research Ethics Committee - CREC), before any study-specific procedure is performed~Exclusion Criteria:~* Known history of convulsive disorders~* Poorly controlled hypertension (diastolic blood pressure \> 100 mmHg) at screening~* Inadequate liver function (total bilirubin \> two times the upper limit of the normal range (ULN), and liver enzymes (ALT, AST) \> two times ULN)~* Inadequate renal function (serum creatinine concentration \> 2 mg/dL)~* Ferritin \< 100 ng/ml or transferrin saturation index (TSI) \< 16%; Vitamin B12 deficiency (\< 200 pg/ml) or folate deficiency (\< 2 ng/ml)~* Clinically-relevant haemorrhages~* Haemolytic anaemia~* Cardiac condition: uncontrolled angina, congestive heart failure, or uncontrolled cardiac arrhythmia~* Clinically significant systemic infection or chronic inflammatory disease present at time of screening~* Any concomitant therapy used to treat MDS (including other growth factors than those described as part of this protocol, chemotherapy, antibody-based cancer treatment, hormonal therapy, interferon, and interleukins)~* Treatment with rHuEPO or darbepoetin alfa over the 4 weeks prior to Day 1 of the study~* More than 2 RBC transfusions over the 28 days prior to Day 1 of the study~* Pregnant or breast feeding women~* Subjects of childbearing-potential who do not take adequate contraceptive measures, in the opinion of the investigator~* Known hypersensitivity to any mammal-derived recombinant product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).